We have previously shown that tumor necrosis factor-a (TNFa) strongly potentiates interleukin-3 (IL-3)-induced shortterm proliferation of human CD34+ hematopoietic progenitor cells (HPC). Using longer term cultures of CD34+ HPC, we demonstrate here that this initial potentiation ceases after 10 to 12 days; whereupon TNFa displays inhibitory effects. 
We have previously shown that tumor necrosis factor-a (TNFa) strongly potentiates interleukin-3 (IL-3)-induced shortterm proliferation of human CD34+ hematopoietic progenitor cells (HPC). Using longer term cultures of CD34+ HPC, we demonstrate here that this initial potentiation ceases after 10 to 12 days; whereupon TNFa displays inhibitory effects. Thus, TNFa was found to inhibit cells of granulocytic affiliation while it potentiates the development of maturing cells of the monocytic lineage both in liquid and semi-solid (day 14 colony-forming unit) cultures. TNFa was demonstrated to reversibly block granulocytic differentiation at the level of uncommitted CD13-, CD15-blast cells that accumulate in TIMULATION of human hematopoiesis depends on S growth factors such as interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte-CSF (G-CSF), and macrophage-CSF (M-CSF). ' The in vitro stimulatory role of these cytokines, first demonstrated on light density bone marrow cells (LD-BMC) was later confirmed using purified hematopoietic progenitor cells (HPC) .'.' In human, these HPC are included in the CD34 compartment that represents 1% to 2% of LD-BMC and contains totipotential progenitors as CD34' HPC can fully reconstitute lethally irradiated baboons. ' Negative regulation of hematopoiesis has been studied on fractionated LD-BMC demonstrating that interferons (IFNs):" transforming growth factor-p (TGFP),'z-'4 and tumor necrosis factors (TNFS)'~.'' can inhibit CSF-dependent in vitro growth of clonogenic cells.
In our efforts aimed at characterizing the response of CD34' HPC to cytokines, we recently found that TNFa enhanced IL-3-and GM-CSF-dependent cell proliferation, through both increased frequency and growth rate of cytokine responsive cells. 21 Because this result appeared in contrast with previously described studies performed with TNFa on LD-BMC fraction^,'^-^ we designed the present study to clarify this issue. Here we show, using purified CD34' HPC, that TNFa is both a stimulator of early IL-3-induced growth and an inhibitor of subsequent IL-3-dependent myelopoiesis. We further demonstrate that the inhibitory activity is directly mediated by TNFa, which, on one side, blocks both early granulocytic differentiation and proliferation of granulocyte-committed cells and, on the other side, favors the development of monocytic cells.
MATERIALS AND METHODS
For the sake of clarity, the experimental protocols used throughout the present study have been schematically represented in Fig 1. Hematopoietic factors and antibodies. Recombinant human IL-322 (kindly provided by Dr S. Tindall, Schering-Research, Bloomfield, NJ) was purified to homogeneity. Specific activity was 5 x lo6 Uimg as previously defined and was used at a saturating concentration of 10 ng/mL (50 UlmL) .'' Recombinant purified TNFa was purchased from Genzyme (Boston, MA) (specific activity, 2 x lo7 U/mg) and was used at a saturating concentration of 25 ng/mL (500 U/mL).*' A monoclonal antibody (MoAb) against TNFa (kindly IL-3 + TNFa cultures. Furthermore, growth of committed granulocytes (CD15+) from IL-3 cultures was also inhibited by TNFa through an arrest of cell cycle in G,/G,. Finally, the use of neutralizing anti-TNFa monoclonal antibody and limiting dilution studies indicate that the inhibitory effects of TNFa are direct. Taken together, our data demonstrate that, following a phase of potentiation of proliferation of early HPC, TNFa displays direct inhibitory effects due to negative interference with both granulocytic differentiation and proliferation of granulocytic cells. o 1991 by The American Society of Hematology.
provided by Dr G.R. Adolf, Bender and Co, GmbH, Vienna, Austria) of 6,000 Uikg neutralizing activitywas used at a concentration of 1 kg/mL.
Umbilical cord blood samples were obtained according to institutional guidelines. Cord blood was collected during normal full-term deliveries in glass vessels containing preservative-free grade-1 sodium heparin (Sigma, St Louis, MO) at a final concentration of 20 IUlmL. Light-density mononuclear cells were isolated by Ficoll-Hypaque gradient separation at a density of 1.077 g/mL. Mononuclear fractions were depleted of adherent cells by overnight incubation at 37°C in RPMI 1640 medium (GIBCO, Grand Island, NY) supplemented with 1% wtkol tissue-culture grade bovine serum albumin (BSA, Boehringer, Mannheim, Germany). Cells bearing CD34 antigen were isolated from nonadherent mononuclear fractions through positive selection by indirect immune "panning" using anti-My10 MoAb (HPCA-1; Becton Dickinson, Mountain View, CA), as reported e l s e~h e r e .~.~ When the purity of the CD34+ isolated cells, as determined by FACScan flow cytometric analysis, was below 95%, a second purification step was performed using a cocktail of MoAbs (Leu-M3  [ Imine, UK), 10 mmoliL HEPES, 2 mmol/L L-glutamine, 5 x lo-' m o m 2-mercaptoethanol, penicillin (100 U/mL), and streptomycin (100 pgimL) (referred to as complete medium).
CD34+ cells were seeded for expansion in 24-well culture plates (Linbro; Flow Laboratories, McLean, VA) at 1 x lo5 cells/mL. Optimal conditions were maintained by splitting these cultures every 4 to 5 days. At different time points as indicated, cells were collected for counting, phenotyping, and cytologic characterization, and establishment of secondary cultures (Fig 1A and C) . For initiation of secondary cultures, cells were washed four times and further incubated for 3 hours in complete medium to eliminate growth factors. Subsequent cultures were established for cell viability determination, cell cycle analysis, and proliferation and clonogenic assays as described below (Fig 1A and C) .
For proliferation assays, cells were distributed in 96-well roundbottom microtest tissue-culture plates (Nunc, Roskilde, Denmark) between 5 x lo' and 2 x lo4 cells/lOO WL complete medium and incubated (37"C, 5% CO,) with saturating concentrations of IL-3 with or without TNFa for 6 days. After incubation, cells were pulsed with 1 WCi of 'H-TdR for 6 hours, harvested, and counted. Tests were performed in triplicate, and results were expressed as mean counts per minute (cpm) f standard deviation.
Semisolid cultures of 1 mL were performed in methylcellulose by plating between 2 x lo3 to 10' cells per tissue-culture grade 35-mm Petri dish (Corning Glass, Corning, NY), in the presence of 1 IU purified recombinant human erythropoietin (Epo; Amgen, Thousand Oaks, CA, specific activity > 7 x lo4 IUimg) as previously described in detail? Duplicate dishes were plated in each experiment, and after 14 days of Progenitor assays in semisolid medium.
incubation at 37°C and 5% CO, colonies ( 2 50 cells) were counted using phase-contrast microscopy.
Cells collected either from liquid or semi-solid cultures were cytocentrifuged for 7 minutes at 400 RPM in a Cytospin-2 (Shandon, Astmoor, UK) in medium containing 50% FBS. Cells were stained with May-Griinwald-Giemsa, and subsequently characterized microscopically.
Cytofluorimetric cell-surface phenovping. Indirect immunofluorescence was performed according to standard techniques, using a panel of murine MoAbs (see below), revealed by fluorescein isothiocyanate (F1TC)-conjugated sheep F(ab')* antimouse Ig (Bio-art, Meudon, France). Double-color fluorescence was performed by sequential incubation of the cells with unconjugated MoAbs, FITC-conjugated antimouse Ig, normal mouse serum, and MoAbs (see below) directly labeled with phycoerythrin (PE). MoAbs used were as follows: anti-LeuM3 and anti-LeuM3-PE (CD14), anti-LeuM1 (CD15), anti-HLA-DR, and anti-HLA-DR-PE (all obtained from Becton Dickinson), and anti-My7 (CD13) (Coulter Immunology, Hialeah, FL). Negative controls were performed with unrelated murine MoAbs. Fluorescence analysis was determined with a FACScan flow cytometer (Becton Dickinson, Sunnyvale, CA).
After 7 days of culture in IL-3 (10 ng/mL) + TNFa (25 ng/mL), cells were collected, washed several times, and labeled by sequential incubation with anti-My7 (CD13) and FITC-conjugated antimouse Ig. Using a FACS 440 (Becton Dickinson), the cells were separated on the basis of CD13 expression into a CD13-fraction and a CD13' fraction ( Fig 1B) . Cells from primary IL-3 cultures were incu-
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For personal use only. on October 30, 2017. by guest www.bloodjournal.org From DUAL EFFECTS OF TNFa ON HEMATOPOIESIS 637 bated for 48 to 72 hours in the presence of IL-3 with or without TNFa, and 0.1 pgimL colcemid (GIBCO) was added during the last 16 hours. Cells were subsequently collected, washed twice in complete medium, and incubated with 10 KmollL Hoechst 33342 dye (Calbiochem, Behring Diagnostics, La Jolla, CA)= at lo6 cells/mL at 37°C for 45 minutes. In some experiments, cells were processed for double-color membrane fluorescence labeling as previously described. Using a FACS 440, cell-surface Ag expression and DNA content were analyzed with the argon laser tuned at 488 nm and the UV argon laser tuned at 354 to 361 nm, respectively (Fig 1C and D) .
During primary culture in IL-3, cells were collected at the timepoints indicated and seeded in 96-well flat-bottom microculture plates (Falcon Labware, Oxnard, CA) at 5 x lo4 cells/well in 100 kL, in presence of IL-3 (10 ng/mL) with or without TNFa (25 ngimL). After 48 hours of incubation, cells were pulsed with 50 &mL M l T [3-(4,5-dimethylthiazol-2-y1)-2,s-diphenyl tetrazolium bromide] (Sigma) at 37°C for 3 hours, as described." Acid-isopropanol (150 p,L of 0.04 N HCI in isopropanol) was added to each well and mixed thoroughly to dissolve the crystals, and the plates were read on a Dynatech MR-580 Microelisa reader (Dynatech, Alexandria, VA), using a test wavelength of 570 nm and a reference wavelength of 630 nm ( Fig 1C) .
Cells precultured in IL-3 for 14 days were washed and recultured in presence of IL-3 with or without TNFa for 72 hours. Experiments were set up in duplicate wells, one well for cell cycle analysis and one for supernatant collection. Supernatants were stored at -20°C and subsequently tested for their inhibitory activity, in the presence of an anti-TNFa MoAb (1 &mL) or a control MoAb of same isotype (1 p,g/mL), on the proliferation of CD34+ HPC precultured for 14 days in IL-3 ( Fig 1E) .
Cells precultured in IL-3 for 14 days were washed and recultured in limiting dilution conditions at one cell per well in 96-well round-bottom microtest tissue-culture plates (Nunc), as previously described:' in Iscove's modified Dulbecco's medium (IMDM) containing 30% FBS, mol/L 2-mercaptoethanol, 0.5% wtivol BSA neutralized with NaHCO,, and L-glutamine and antibiotics as indicated above. For each factor tested, aliquots of 50 pL were seeded in 600 wells. After 6 days of culture (37"C, 5% CO,), positive wells were scored and the number of cells in each clone was determined using an inverted microscope coupled to an automated image analysis system (Biocom, Paris, France). Clone frequency was determined as the log of the fraction of nonresponding wells and average clone size was calculated as the ratio of the total cell number enumerated in the 600 wells seeded to the number of responding cells present in the 600 wells observedzs (Fig 1F) .
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RESULTS
Agonistic and antagonistic effects of TNFa on the response of CD34' HPC to IL-3. As we recently reported," TNFa enhances the early proliferative response of CD34' HPC to IL-3 in liquid cultures, and consequently twofold to threefold more viable cells can be recovered after 5 to 10 days of culture in IL-3 + TNFa when compared with IL-3 alone (Fig 2) . However, after 10 days of culture, cell proliferation halted in cultures containing IL-3 + TNFa, whereas proliferation persisted in IL-3 alone. Thus, after 32 to 34 days, two to six times more viable cells were generated in IL-3 cultures than in IL-3 + TNFa cultures (Fig 2) .
When CD34+ HPC were plated in semi-solid medium, TNFa was found to enhance the generation of day 7 IL-3-dependent colonies, whereas at day 14 IL-3-and Epo-dependent colonies were inhibited (Table 1) . TNFa totally blocked the generation of burst-forming uniterythroid (BFU-e) and mixed erythroid (E-MIX) colonies, strongly inhibited the generation of GM colonies, and reduced the numbers of G colonies by 50%. In contrast, TNFa did not affect the generation of M colonies.
Characterization of cells obtained in IL-3 + TNFa cultures.
To further analyze the modulatory effects of TNFa on IL-3-dependent proliferation of CD34' HPC, we performed, at various time intervals, cytologic and phenotypic characterization of cells generated in the liquid cultures (Fig 1A) . Cytologic analysis (Fig 3) demonstrated that more monocytes/macrophages ( Fig 3A) and fewer granulocytes ( Fig 3B) were observed in the presence of IL-3 + TNFa as compared with IL-3 alone. This effect was observed as early as 6 days of culture, and became more evident as cultures progressed. Thus, after 18 days, the proportions of monocytes/macrophages and of granulocytes were, respectively, in thc prcscncc of IL-3 + TNFa, the pcrcentagc of cells cxprcssing thc myclomonocytic CD13 antigen'" was reduccd as a conscqucncc of an important cxpansion of CD13-cclls (fourfold to sixfold the number obtained in IL-3 alonc aftcr 6 days of culture).
Cells prcculturcd in IL-3 or IL-3 + TNFa were further assessed for colony-forming ability in semi-solid medium (Fig 1A) . The frequency (Fig 5 ) and size (not shown) of mycloid colony-forming units (CFU) steadily dccrcascd in presence of either IL-3 or IL-3 + TNFa. However, these events occurred earlier in the prescncc of TNFa. as illustrated by five times fewer CFU at day 12 (Fig 5) . During the culture in the presence of IL-3, the proportion of CFU-M was nearly constant, representing 25% to 35% of the total CFU. In marked contrast, thc combination of IL-3 + TNFa resulted in an increascd proportion of CFU-M from 35% at day 0 to 90% of total CFU at day 18. CFU-GM, E-MIX, and BFU-e were no longer detcctcd after 6 days of preculturc in either IL-3 or IL-3 + TNFa (not shown).
Whcn assessed in absolute numbers, 15 to 25 times more CD15+ granulocytic cells and 20 to 100 times more CFU-G were obtaincd after 18 days of culture in IL-3 alone when compared with IL-3 + TNFa. In contrast, while thc CD14' monocytic cclls and the CFU-M were, respectively, 4 to 8 and 4 to 30 timcs morc numcrous in IL-3 + TNFa than in IL-3 alone at day 12, no significant quantitative diffcrcnces could be obscrved at day 18 (not shown).
Thus, TNFa appcars to simultaneously block granulocytic devclopment, as defined by CFU-G generation and CD13/CD15 antigen expression, and to potentiate the dcvelopment of monocytic-lineage cells.
For CD13-and CD13' cclls wcrc FACS-sorted from day 7 culturcs performcd in IL-3 + TNFu. washcd, and subsequcntly rcculturcd for 7 morc days with IL-3 or with IL-3 + TNFu (Fig 1B) . Phcnotypic analysis (Fig 6) indicatcd that a largc percentage of thc CD13-sortcd cclls acquired CD13 (30% to 60%; thrcc scparatc cxpcrimcnts) and CD15 (25% to 40%) whcn rcculturcd for 7 days with IL-3 alonc. In contrast, whcn rcculturcd with IL-3 + TNFa, thc CD13-sortcd cclls wcrc unable to cxprcss cithcr CD13, CD15, or CD14, dcspite sustained prolifcration. In parallel, the CD13+ sortcd cells remained CD13+ when reculturcd with IL-3, expressing either CD15 or CD14, and addition of TNFu did not affcct their phenotype. Takcn togcthcr, thcsc data indicate that TNFu spccifically blocks granulocyte diffcrcntiation at the level of CD13-cclls, and that this cffcct is rcvcrsiblc because removal of TNFu from culturcs results in subscqucnt IL-3-drivcn granulocytic diffcrcntiation.
TNFu inhibits IL-3-dependent proliferation of granulocytecommitted cells. Becausc TNFu has been characterized for its cytolytic activity on various cell types," we investigated whether such an effect could account for the TNFuinduced growth inhibition observed in later stages of IL-3-dcpcndent cultures. Thus, CD34' HPC were cultured for up to 26 days with IL-3 alone. At various timc intcrvals, cells wcrc harvcsted and reculturcd with cither IL-3 alonc or IL-3 + TNFu and thrcc biologic parameters were subsequently studied (Fig 1C) : (1) To furthcr clarify thc inhibitory effects of TNFu on the latcr stagcs of IL-Mcpendent cell growth and differcntiation, multicolor flow cytomctric analysis was performcd to corrclatc the phcnotype (expression of two surface antigens) with cellular DNA content (as measured by Hocchst 33342 staining). Target cells were culturcd for 12 days with IL-3, then recultured for 3 additional days with IL-3 with or without TNFu (Fig 1D) . As illustrated in Table 2 , TNFu reduced by approximately 20% the number of S/G,M cells (see column total). Half of the culturcd cells were CD15' HLA-DR-(granulocyte-committcd cclls) and addition of TNFa strongly inhibitcd (mcan inhibition 28.6%) the entry of these cells into S/G,M. Approximately one-third of the cultured cells were CD15-HLA-DR-(undcfincd maturing cells that lacked exprcssion of CD14) with a rclatively low proliferation rate (14.7% of cclls in cyclc), and were not significantly affccted by TNFu. The minor population of blast cells expressing HLA-DRh but ncither CD14 nor CD15 (1 1% of total cclls) displayed an intense proliferative or IL-3 + TNFa I+). 3 . For personal use only. on October 30, 2017. by guest www.bloodjournal.org From days in presence or absence of TNFa (see Materials and Methods and Fig ID) .
incubation in IL-3 or in IL-3 + TNFa as no differences were observed.
anti-TNFa-neutralizing MoAb or a control MoAb ( Fig   1E) . As shown in Table 3 , supernatants obtained in TNFa cultures inhibited the growth of CD34' HPC cultured for 14 days in IL-3 alone and the anti-TNFa MoAb, in contrast to the control MoAb, completely reverted this inhibition. Supernatants of cells cultured with IL-3 alone did not affect cell proliferation regardless of the presence of anti-TNFa MoAb. This result indicates that supernatants contain no soluble factors, other than TNFa, responsible for the inhibitory activity. To further confirm that TNFa directly inhibits growth, CD34+ cells cultured for 14 days with IL-3 were washed and recultured at 1 cell per well with IL-3 with or without TNFu (600 wells per culture condition) (Fig 1F) . After 6 days, the number of positive wells and the number of cells in each positive well were determined (Fig 8) . While clone size was not affected (average size, 11.9 cells/clone in Cells precultured in IL-3 for 14 days were washed and recultured in the presence of IL-3 with or without TNFa for 72 hours. Supernatants were collected and subsequently tested for their inhibitory activity, in the presence of a neutralizing anti-TNFu MoAb (1 Fg/mL) or an unrelated control MoAb (1 FglmL), on the proliferation of CD34+ HPC precultured for 14 days in IL-3 (see Materials and Methods and Fig 1E) . 
DISCUSSION
In a previous study we demonstrated that TNFa strongly potentiates the early proliferative response of CD34' HPC to IL-3 and GM-CSF.*' Here, we explored the effects of TNFa on longer term in vitro proliferation and differentia- The present study also indicates that TNFa strongly inhibits IL-3-dependent erythropoiesis from CD34' HPC, in agreement with results previously published with fractionated LD-BMC.l5-I9 However, the mechanisms involved in TNFa-mediated inhibition of erythropoiesis have not been explored. In contrast to the above mentioned effects, TNFa did not decrease the number of recruited CFU-M and even potentiated IL-3-dependent development of the monocytic lineage in liquid cultures of CD34' HPC. These findings are in accordance with reports indicating a lack of inhibitory effect of TNFa on the development of CFU-M'9,20 and a capacity of TNFa to enhance macrophage proliferation in synergy with M-CSF.34 However, the monocytic cells that acquire CD14 become slowly proliferating cells, therefore the TNFa-dependent early potentiation of monocyte development subsequently contributes to the arrest of growth progression observed in late cultures. In addition, CD14+ monocytes become sensitive to cycle inhibition by TNFa, which could be related to an induction of differentiation as described on promyelocytic cell line^.'^,^^,^^ Our data indicate that the inhibitory effects of TNFa are direct, as previously demonstrated for the early potentiating activity.'l The mechanisms by which TNFa displays stimulatory effects on undifferentiated HPC and inhibitory effects on granulocyte-committed cells remain to be determined. In this context, TNFa has been shown to upregulate the expression of the IL-2 receptor on activated T cells3' and the TGFP receptor on promyelocytic and monocytic leukemic cell lines," suggesting that the dual effects of TNFa could be due to differential modulation of CSF receptors in relation to lineage and differentiation stage of the cells. However, differential cell sensitivity to TNFa could involve the two distinct TNFa receptor^'^ for which specific cDNAs have recently been ~l o n e d .~-~' The availability of specific probes for the TNFa receptors will allow studies of their expression on cells generated in the presence of IL-3.
Finally, our studies on the agonistic and antagonistic effects of TNFa on in vitro hematopoiesis shed new light on the contrasting in vivo effects of TNFa, as reports have described both and inhibitory46 effects on myelopoiesis. Our present results suggest that both, in vivo, stimulatory effects, previously ascribed to TNFa-mediated cytokine p r~d u c t i o n ,~~,~~-~~ and inhibitory effects could be due to direct actions of TNFa.
TNFa, primarily identified as a cytotoxic factor, was later demonstrated to display growth stimulating properties on different cell type^?^.^^ In this context, TNFa has been shown to enhance GM-CSF and IL-3,56,57 but to inhibit G-CSF" induced in vitro growth of acute myeloid leukemias. Such a capacity to display both proliferative and antiproliferative effects is indeed shared by many factors.'* In our studies, we have demonstrated that TNFa directly potentiates early normal hematopoiesis and inhibits subsequent granulocytic development, while it enhances monocytic expansion, suggesting a crucial and complex role for this cytokine in the regulation of hematopoiesis. 
